Status:
COMPLETED
Changes in Blood Gases, Disturbance of Breath During Sleep and Cardiovascular Co-morbidity in COPD Patients
Lead Sponsor:
LHL Helse
Collaborating Sponsors:
Stiftelsen Helse og Rehabilitering
Landsforeningen for hjerte og lungesyke (LHL)
Conditions:
Pulmonary Disease
Chronic Obstructive
Eligibility:
All Genders
Phase:
NA
Brief Summary
Respiration failure type 2 is loss of the lungs ability to take up oxygen (O2) and get rid of carbon dioxide (CO2). The diagnosis is based on blood gas measurement of pressures of O2 and CO2. Patients...
Eligibility Criteria
Inclusion
- COPD (FEV1 \< 80 % of pred. and FEV1/FVC \< 0,7)
Exclusion
- other serious disease (like lung cancer, sarcoidosis, restrictive lung disease)
- exacerbation of COPD within 3 weeks before inclusion
- coronary heart disease with unstable angina pectoris or myocardial infarction within 3 months of incl.
- uncontrolled hypertension
- cerebral infarction
- neurological, muscular or skeletal disease/disorder that affect abdominal- and/or thoracal movements (kyphoscoliosis, paresis, etc)
- unstable diabetes mellitus or signs of organ failure (anaemia, kidney failure, liver failure, etc)
- misuse/dependency of alcohol, sedatives, neurostimulating or narcotic drugs)
- obstructive sleep apnoea/hypopnoea syndrome
- using CPAP/BiPAP or home respirator
- pregnancy
- if PSG shows AHI \> 30, or if patient becomes acutely ill between the nights with PSG, he/she will be withdrawn from the study
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00888342
Start Date
May 1 2009
End Date
July 1 2011
Last Update
May 16 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Glittreklinikken
Hakadal, Akershus, Norway, 1485
2
Glittreklinikken
Oslo, Hakadal, Norway, 1485